Children and young people
Different inherited sight loss conditions present noticeable symptoms at different times.
Search
Search results
Exciting developments for new treatment research
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Look Forward – Summer 2024 – Issue 183
This edition includes exciting news about our Annual and Professionals’ Conferences. We hope as many of you as possible can join us in Manchester, or online, in September. You’ll also find updates about the latest research and a feature on one of our funded researchers, Dr Jörn Lakowski.
Look Forward – Autumn 2025 – Issue 187
Since the publication of this newsletter our founder and honorary president Lynda Cantor MBE has passed away. We are all deeply saddened by this news.
e-Newsletter September 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Nanoscope Announces topline results from randomised phase 2B trial of MCO-010 for retinitis pigmentosa
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
Look Forward – Spring 2024 – Issue 182
Inside this edition, set yourself a challenge in 2024, plus find out about our brand new lottery.
Disability sector calling for cost of living support
Retina UK has joined with more than 80 disability charities who have today written to the Chancellor calling for urgent support with the cost of living for disabled people.
Research brings hope for the future
“All the promising research makes you feel like there is light at the end of that very dark tunnel after all.”
Light sensing small molecule given green light
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.